First Day of North American CF Conference Highlights Latest Advancements in CF Research, Care and Drug Development
October 12, 2012
The 26th annual North American Cystic Fibrosis Conference (NACFC) kicked off yesterday in Orlando, where nearly 4,000 researchers, physicians, caregivers and other medical professionals gathered to discuss the latest results of research studies, ways to improve CF care and breakthroughs in cystic fibrosis treatments.
Cam McLoud, chair of the Cystic Fibrosis Foundation board of trustees, welcomed attendees to the first plenary by highlighting recent milestones in the fight against CF — focusing particularly on the FDA’s approval of KalydecoTM, the first drug to treat the underlying cause of CF in a small group of people with the disease. She thanked the scientists and researchers for their hard work in developing the drug, clinicians who led important clinical trials of Kalydeco and people with CF who participated in those trials.
“I know that you will not stop using your talents to find a cure for CF,” she said to the audience. “And I can assure you that the Cystic Fibrosis Foundation also will not rest until all people with CF — every single one of them — will never have to worry about CF again.”
Following her opening remarks was a message from Scott Pelley, CBS Evening News anchor and long-time supporter of the CF Foundation.
Steven M. Rowe, M.D., M.S.P.H, of the University of Alabama at Birmingham and William Skach, M.D., of Oregon Health and Science University capped off the first day with their plenary presentations on efforts to discover and develop more potential therapies that treat the underlying cause of CF in all people living with the disease.
Watch Scott Pelley’s message to NACFC attendees:
Check out photos from NACFC in our Facebook album.